Cytek Biosciences, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Numerator | |||||||||||||||||
| Net loss | $ | (66,539) | $ | (6,020) | $ | (12,148) | |||||||||||
| Less: net loss allocated to noncontrolling interests | — | — | — | ||||||||||||||
| Net loss attributable to common stockholders, basic and diluted | $ | (66,539) | $ | (6,020) | $ | (12,148) | |||||||||||
| Denominator | |||||||||||||||||
| Weighted-average common shares outstanding, attributable to common stockholders, basic | 127,745,939 | 130,611,330 | 135,283,044 | ||||||||||||||
| Effect of employee stock plans | — | — | — | ||||||||||||||
| Weighted-average common shares outstanding, attributable to common stockholders, diluted | 127,745,939 | 130,611,330 | 135,283,044 | ||||||||||||||
| Net loss attributable to common stockholders per share, basic | $ | (0.52) | $ | (0.05) | $ | (0.09) | |||||||||||
| Net loss attributable to common stockholders per share, diluted | $ | (0.52) | $ | (0.05) | $ | (0.09) | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Mar 13, 2024 | |
| 2022 | Mar 1, 2023 | |
| 2021 | Mar 17, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.